AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amylyx Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.33+0.99 (+3.76%)
Close on Oct 19, 2026
- Market cap
- $3.04B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$12.38 (+82.81%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Amylyx Pharmaceuticals, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$123.48M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$162.10M
TTM Q2 2026
Free cash flow
-$123.48M
FY2025
EPS, diluted
-$1.43
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $3.04B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 12.71
- Dividend yield
- –
- Free cash flow yield
- -4.06%
Fundamentals
- Revenue
- $0
- Net income
- -$152.09M
- EPS, diluted
- -$1.43
- Free cash flow
- -$123.48M
- Book value per share
- $2.15
- Diluted shares
- 111M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$162.10M
Net income
-$152.09M
EPS, diluted
-$1.43
Free cash flow
–
Reported periodTrailing twelve months